Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCLH801
- Development stage
- Phase 1
- Lead developer
- UTC Therapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UCLH801 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target Cadherin-17 (CDH17), a calcium-dependent cell adhesion molecule. CDH17 is highly expressed in various gastrointestinal malignancies, including colorectal, gastric, and pancreatic cancers, while displaying limited expression in normal tissues, making it a promising target for selective immunotherapy. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes CDH17, enabling the T cells to identify and eliminate tumor cells upon re-infusion. UCLH801 is currently undergoing Phase 1 clinical evaluation (NCT06937567) to determine its safety, tolerability, and preliminary efficacy across a range of CDH17-positive advanced solid tumors.
- Other names
- CDH17 CAR-TCDH-17 CAR-TCDH 17 CAR-TCDH17 CAR-T cellsCDH-17 CAR-T cellsCDH 17 CAR-T cells
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on UCLH801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCLH801.